The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Biomarkers Of Phenotype, Prognosis And Response To Therapy In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$105,845.00
Summary
Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.
Australian Prostate Cancer Collaboration (APCC) Bio-Resource
Funder
National Health and Medical Research Council
Funding Amount
$2,310,000.00
Summary
The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office ....The Australian Prostate Cancer Collaboration (APCC), supported by the Commonwealth Bank, Prostate Cancer Foundation of Australia and Andrology Australia, has been developing an Australia-wide network of prostate tissue banks and associated clinical databases for the past 3 years. The concept of this innovative project is to establish “nodes” or branches of the tissue bank in each State where tissues are collected and to coordinate the use of this material from a central committee or “head office”. A website has been established (www.apccbioresource.org.au) that is the national face of this ‘virtual’ national tissue bank and 7 State-based tissue bank consortiums are participating in this venture. The goal of this ‘virtual bank’ or network is to further enhance the national research effort by facilitating greater collaboration nationally and providing better access to, and optimal utilisation of, the clinical material available to facilitate improvements in prostate cancer management. Operational support for the nodes is critical for the success of a national Bio-Resource.Read moreRead less
How Does Fra-1 Regulate The Invasive Properties Of Tumour Cells?
Funder
National Health and Medical Research Council
Funding Amount
$468,119.00
Summary
Most cancer deaths occur when tumours spread and destroy vital body functions. The invasion of tumour cells into surrounding tissue is a critical step during the spread of cancer. This project aims to unravel the molecular mechanisms that control the ability of tumour cells to invade into surrounding tissue and subsequently spread to other sites in the body. We expect to identify potential targets to better diagnose and treat the spread of cancer.
Epigenetic Silencing Of Large Chromosomal Regions In Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$745,356.00
Summary
Epigenetics is a term that desribes modification of gene expression without a change to the DNA sequence through processes that involve chemical change to the DNA such as methylation. In this grant we will further characterise and understand the mechanism involved in long range epigenetic silencing and determine its prevalence in prostate cancer. This study will provide potential novel targets for prostate cancer detection, prognosis and therapy.
Molecular Mechanisms That Mediate The Anti-osteosarcoma Properties Of Pigment Epithelium-derived Factor (PEDF)
Funder
National Health and Medical Research Council
Funding Amount
$123,453.00
Summary
Cancer results from a sequence of alterations to genes which lead to abnormal cells dividing without control. Osteosarcoma is a cancer involving bone and can rapidly spread to surrounding and distant tissues. A number of mediators have been identified as being able to provide some regulation of this abnormal cell division. Pigment epithelium-derived factor is one such protein and further understanding of how it achieves this could be used for the development of targeted osteosarcoma treatment.
Characterisation Of The Molecular Pathogenesis Of Cancer Cachexia Syndrome In Colorectal Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$100,381.00
Summary
Cachexia is a hypermetabolic wasting syndrome involving depletion of both fat and muscle which affects 80% of cancer patients. The exact mechanisms of this syndrome are unknown at the molecular level and this affects our ability to predict, prevent or treat this problem. This study aims to elucidate the molecular mechanisms of cancer cachexia syndrome with a view to implementing nutritional, exercise and pharmacological interventions to prevent its onset.
CHARACTERIZATION OF THE NOVEL LEUKEMIA-INDUCING GENE MLF1
Funder
National Health and Medical Research Council
Funding Amount
$393,750.00
Summary
All of the circulating blood cells (including red cells and white cells) arise from haemopoietic stem cells found in the adult bone marrow. Stem cells gradually develop into one cell type. Once they have started down a particular pathway, they no longer generate cells of another pathway (e.g. once a stem cell begins to develop into red blood cells, they do not change into white cells). However, there are a few examples of mature cells that have changed pathways. We generated a red blood cell lin ....All of the circulating blood cells (including red cells and white cells) arise from haemopoietic stem cells found in the adult bone marrow. Stem cells gradually develop into one cell type. Once they have started down a particular pathway, they no longer generate cells of another pathway (e.g. once a stem cell begins to develop into red blood cells, they do not change into white cells). However, there are a few examples of mature cells that have changed pathways. We generated a red blood cell line, which has on occasions changed into macrophages (white blood cells) when grown under stressful conditions. Using these cells, we identified a gene, HLS7, which was involved in the change to macrophages. An American group has independently shown this gene can cause leukemia (blood cancer). We have shown HLS7 has dramatic effects on normal blood development and, together with its effect on leukemias, demonstrates its importance to the blood system. Through our studies on how HLS7 works, we have identified another gene, Madm, which may be an important regulator of HLS7. We plan to investigate the normal function of HLS7, how it interacts with Madm and how it causes leukemias. Analysis of these genes will further our knowledge in this field of blood cell development and cancer formation.Read moreRead less
The Molecular Function And Role Of The New Metastasis Suppressor NDRG1 In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$226,425.00
Summary
With cancer now a leading cause of death in Australia, finding new ways to treat this disease is crucial. Iron is critical for cancer cell growth and metastasis, thus agents that bind iron (called iron chelators) can be used to treat cancer. These drugs up-regulate the gene NDRG1, which has been shown to prevent tumour spread. The role of NDRG1 in tumour growth and spread of cancer cells will be examined as this may lead to novel therapies against cancer (e.g. the use of novel iron chelators).
Analysis Of The Apoptotic And Therapeutic Effects Of Histone Deacetylase Inhibitors On Multiple Myeloma
Funder
National Health and Medical Research Council
Funding Amount
$287,321.00
Summary
Multiple myeloma (MM) is an incurable progressive cancer of plasma cells within blood. It is the second most common blood cancer and represents 2% of all cancer-related deaths. Statistics show increasing incidence and decreasing age of onset. The cause and progression of MM is poorly understood and current treatments are frequently followed by relapse. This project will assess exciting new therapies against the survival of MM cells leading to more effective treatments in the future.
Defining Steps In The Molecular Pathogenesis Of Lung Cancer Using Immortalized Human Bronchial Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$374,344.00
Summary
Lung cancer remains the leading cause of cancer death worldwide and is caused by abnormalities in DNA. This project aims to further our understanding of this disease by altering known cancer-related genes and studying their effect on lung cancer development. This project also aims to identify novel genes in lung cancer as well as tumour expression profiles which can predict response to chemotherapy agents. In summary, this research will identify new gene targets for therapeutic agents.